Article Text

other Versions

PDF
Clinicopathological significance of CADM4 expression in invasive ductal carcinoma of the breast
  1. Se Min Jang1,
  2. Jongmin Sim1,
  3. Hulin Han1,
  4. Hye In Ahn1,
  5. Hyunsung Kim1,
  6. Kijong Yi1,
  7. Young Jin Jun1,
  8. Abdul Rehman1,
  9. Min Sung Chung2,
  10. Kiseok Jang1,
  11. Seung Sam Paik1
  1. 1Department of Pathology College of Medicine, Hanyang University, Seoul, South Korea
  2. 2Department of Surgery, College of Medicine, Hanyang University, Seoul, South Korea
  1. Correspondence to Seung Sam Paik, Department of Pathology, College of Medicine, Hanyang University, #17 Haengdang-dong, Sungdong-ku, Seoul 133-792, South Korea; sspaik{at}hanyang.ac.kr

Abstract

Aims Cell adhesion molecule 4 (CADM4) is a novel tumour suppressor involved in cell adhesion. Loss or decreased expression of CADM4 has been associated with the development and progression of some cancers. The purpose of this study was to investigate the clinicopathological significance of CADM4 expression in breast cancer.

Methods We constructed tissue microarrays to evaluate the immunohistochemical expression of CADM4 in 256 cases of invasive ductal carcinoma (IDC) and 45 cases of ductal carcinoma in situ (DCIS).

Results CADM4 was expressed in 37 (82.2%) DCIS cases, and in 173 (67.6%) IDC cases. CADM4 expression was higher in DCIS than in IDC (p=0.049). Loss or decrease of CADM4 expression was significantly correlated with higher histological grade (p=0.020), absence of oestrogen receptors (p<0.001), absence of progesterone receptors (p=0.024), and overexpression of c-erbB-2 (p=0.018). In univariable and multivariable Cox regression analyses of all 256 IDC cases, CADM4 expression was not significantly associated with overall and disease-free survival. However, it showed a significant positive association with longer disease-free survival in 187 stages I and II IDC cases (p=0.039, log-rank test).

Conclusions Loss or decrease of CADM4 expression seems to play an important role in breast cancer invasiveness, and it is associated with poorer biological parameters. CADM4 can be used as a novel marker predicting risk of recurrence and disease outcomes in stages I and II IDC.

  • Immunohistochemistry
  • Breast Cancer
  • Breast

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.